Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006636681
Mon, 12.06.2023
va-Q-tec AG
Publication of inside information pursuant to Art. 17 (1) of Regulation (EU) 596/2014 on market abuse (Market Abuse Regulation)
Takeover Offer by Fahrenheit AcquiCo GmbH – Clearance by the Federal Cartel Office
Würzburg, 12. June 2023. va-Q-tec AG (ISIN DE0006636681 / WKN 663668) announces that the German Federal Cartel Office (Bundeskartellam [ … ]
Mon, 12.06.2023
va-Q-tec AG
Publication of inside information pursuant to Art. 17 (1) of Regulation (EU) 596/2014 on market abuse (Market Abuse Regulation)
Takeover Offer by Fahrenheit AcquiCo GmbH – Clearance by the Federal Cartel Office
Würzburg, 12. June 2023. va-Q-tec AG (ISIN DE0006636681 / WKN 663668) announces that the German Federal Cartel Office (Bundeskartellam [ … ]
Tue, 23.05.2023
va-Q-tec AG
va-Q-tec reports subdued start to 2023 – revenue growth expected to pick up over the course of the year
Slight decrease in revenues of -3% in Q1 2023 to EUR 27.2 million compared to EUR 28.0 million in Q1 2022
Very dynamic growth in the Products business (+28%), especially in the refrigeration equipment area
Transaction costs, higher energy co [ … ]
Tue, 23.05.2023
va-Q-tec AG
va-Q-tec reports subdued start to 2023 – revenue growth expected to pick up over the course of the year
Slight decrease in revenues of -3% in Q1 2023 to EUR 27.2 million compared to EUR 28.0 million in Q1 2022
Very dynamic growth in the Products business (+28%), especially in the refrigeration equipment area
Transaction costs, higher energy co [ … ]
Fri, 28.04.2023
va-Q-tec AG
va-Q-tec reports revenue growth in FY 2022
Group revenues up 7.5 % to EUR 111.8 million despite sharp reduction in Covid-19 vaccine shipments; non-Covid-19 business continues strong growth
Adjusted EBITDA of EUR 15.7 million corresponds to an adjusted EBITDA margin on revenues of 14 %
For 2023, the Management Board expects a revenue level o [ … ]
Fri, 28.04.2023
va-Q-tec AG
va-Q-tec reports revenue growth in FY 2022
Group revenues up 7.5 % to EUR 111.8 million despite sharp reduction in Covid-19 vaccine shipments; non-Covid-19 business continues strong growth
Adjusted EBITDA of EUR 15.7 million corresponds to an adjusted EBITDA margin on revenues of 14 %
For 2023, the Management Board expects a revenue level o [ … ]
Thu, 20.04.2023
va-Q-tec AG
va-Q-tec notifies concerning the date of publication of its separate and consolidated financial statements for the 2022 financial year, as well as of its quarterly statement for the first three months of 2023
Würzburg, 20 April 2023 va-Q-tec AG (the “Company”) announces that, by way of divergence from the previous scheduling, the publication of [ … ]
Thu, 20.04.2023
va-Q-tec AG
va-Q-tec notifies concerning the date of publication of its separate and consolidated financial statements for the 2022 financial year, as well as of its quarterly statement for the first three months of 2023
Würzburg, 20 April 2023 va-Q-tec AG (the “Company”) announces that, by way of divergence from the previous scheduling, the publication of [ … ]
Mon, 27.03.2023
va-Q-tec AG
va-Q-tec postpones publication of its separate and consolidated financial statements for the 2022 financial year
Würzburg, 27 March 2023 va-Q-tec AG (the “Company”) has postponed the publication of its audited and certified separate and consolidated financial statements for the financial year ending 31 December 2022, until 21 April 2023. This [ … ]
Mon, 27.03.2023
va-Q-tec AG
va-Q-tec postpones publication of its separate and consolidated financial statements for the 2022 financial year
Würzburg, 27 March 2023 va-Q-tec AG (the “Company”) has postponed the publication of its audited and certified separate and consolidated financial statements for the financial year ending 31 December 2022, until 21 April 2023. This [ … ]